A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome
<p>Abstract</p> <p>Background</p> <p>About 80% of patients with GIST would experience tumor recurrence or metastasis after radical resection. The most common site of the metastasis is the liver. Imatinib mesylate has been proved effective for advanced GIST. The present...
Main Authors: | Jiang Ming, Zhou Lin, Yang Yu, Zhu Jiang, Hou Mei |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-05-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/10/199 |
Similar Items
-
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
by: Sumin Tang, et al.
Published: (2017-04-01) -
Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate
by: Jan Yi-Yin, et al.
Published: (2006-10-01) -
Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment
by: Isabelle Deshaies, et al.
Published: (2010-09-01) -
Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
by: Omar S Din, et al.
Published: (2008-03-01) -
Recurrent Gastrointestinal Stromal Tumors in the Imatinib Mesylate Era: Treatment Strategies for an Incurable Disease
by: Rebecca M. Platoff, et al.
Published: (2017-01-01)